Michael Matson
Stock Analyst at Needham
(2.62)
# 2,097
Out of 5,135 analysts
25
Total ratings
69.23%
Success rate
11.46%
Average return
Main Sectors:
Stocks Rated by Michael Matson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TFX Teleflex | Maintains: Buy | $408 → $423 | $112.51 | +275.97% | 4 | Jan 31, 2020 | |
| INGN Inogen | Upgrades: Buy | $90 | $5.83 | +1,443.74% | 2 | Nov 6, 2019 | |
| MMSI Merit Medical Systems | Initiates: Buy | $53 | $82.90 | -36.07% | 1 | Apr 20, 2018 | |
| GMED Globus Medical | Upgrades: Buy | n/a | $90.15 | - | 1 | Apr 4, 2018 | |
| RMD ResMed | Upgrades: Hold | n/a | $258.91 | - | 1 | Jan 23, 2018 | |
| BSX Boston Scientific | Upgrades: Strong Buy | n/a | $76.28 | - | 1 | Dec 8, 2017 | |
| KTWO K2 Capital Acquisition | Downgrades: Buy | n/a | $10.05 | - | 2 | Dec 8, 2017 | |
| LIVN LivaNova | Upgrades: Buy | n/a | $67.42 | - | 2 | Sep 15, 2017 | |
| SYK Stryker | Upgrades: Hold | n/a | $377.32 | - | 4 | Aug 25, 2017 | |
| MBLY Mobileye Global | Downgrades: Hold | n/a | $9.10 | - | 1 | Mar 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $75.20 | - | 2 | Feb 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $90.12 | - | 1 | Aug 12, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.71 | - | 1 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.61 | - | 1 | Feb 24, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $600.40 | - | 1 | Jan 29, 2016 |
Teleflex
Jan 31, 2020
Maintains: Buy
Price Target: $408 → $423
Current: $112.51
Upside: +275.97%
Inogen
Nov 6, 2019
Upgrades: Buy
Price Target: $90
Current: $5.83
Upside: +1,443.74%
Merit Medical Systems
Apr 20, 2018
Initiates: Buy
Price Target: $53
Current: $82.90
Upside: -36.07%
Globus Medical
Apr 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $90.15
Upside: -
ResMed
Jan 23, 2018
Upgrades: Hold
Price Target: n/a
Current: $258.91
Upside: -
Boston Scientific
Dec 8, 2017
Upgrades: Strong Buy
Price Target: n/a
Current: $76.28
Upside: -
K2 Capital Acquisition
Dec 8, 2017
Downgrades: Buy
Price Target: n/a
Current: $10.05
Upside: -
LivaNova
Sep 15, 2017
Upgrades: Buy
Price Target: n/a
Current: $67.42
Upside: -
Stryker
Aug 25, 2017
Upgrades: Hold
Price Target: n/a
Current: $377.32
Upside: -
Mobileye Global
Mar 14, 2017
Downgrades: Hold
Price Target: n/a
Current: $9.10
Upside: -
Feb 15, 2017
Upgrades: Buy
Price Target: n/a
Current: $75.20
Upside: -
Aug 12, 2016
Downgrades: Hold
Price Target: n/a
Current: $90.12
Upside: -
Mar 3, 2016
Downgrades: Neutral
Price Target: n/a
Current: $1.71
Upside: -
Feb 24, 2016
Downgrades: Hold
Price Target: n/a
Current: $3.61
Upside: -
Jan 29, 2016
Upgrades: Buy
Price Target: n/a
Current: $600.40
Upside: -